Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 53,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with 350 employees and 3 different offices located in north, central and south Taiwan. With core business in Human Pharm and Animal Health, we support patients in the area of the respiratory, oncology, diabetes, cardiovascular, stroke, Parkinson's disease, fibrosis disease and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease and chronic kidney disease, also support livestock farmer in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.

More information about Boehringer Ingelheim:
www.boehringer-ingelheim.com (Corporate Website)
www.boehringer-ingelheim.tw (Taiwan Website)
www.facebook.com/1985BITW (Social Innovation Facebook Page)
http://annualreport.boehringer-ingelheim.com (2022 Annual Report)
https://line.me/R/ti/p/%40lxh2761d (LINE@ Official account)
www.boehringer-ingelheim.tw/MAP (Media Map)

www.boehringer-ingelheim.tw/SD4G (Sustainable Development - For Generations)

* To be used from April 7, 2023 until the Annual Results Press Conference in 2024